Treating hernias in children
A hernia occurs when a part of the intestine pushes through a weak spot in the stomach muscles. In children, hernias usually occur in one of two places.
Ovarian cancer recurrence and prognosis
Ovarian cancer recurrence is when the disease returns after being undetectable. Many people with ovarian cancer experience a recurrence at some point.
Epithelial ovarian cancer: What to know
Epithelial ovarian cancer is the most common type of ovarian cancer. It can be easier to treat in the early stages, but as it progresses, it becomes much harder to fully cure.
HRT and ovarian cancer: Is there a link?
Hormone replacement therapy (HRT) is a standard approach to menopause symptom management. However, some people have concerns about a potential link between HRT and ovarian cancer.
Cancer cells: How they shrink or grow larger to survive
A new study, published in the journal Science Advances and funded by The Institute of Cancer Research, is using advanced image analysis and DNA/protein examination to investigate the size regulation of melanoma cells, a type of skin cancer.
Researchers discover the mechanism by which tumor cells become resistant to chemotherapy in colorectal cancer
A large number of cancer patients are treated with platinum-based therapy. However, many tumors are capable of developing resistance to treatment. In this study, the researchers examined tumor samples from patients and pre-clinical models of colorectal cancer to better understand the resistance to platinum-based therapy. They observed that platinum accumulates prominently in the healthy cells that surround the cancer cells, particularly in fibroblasts, the cells that contribute to tissue formation. Furthermore, this accumulation persists for more than two years after treatment has been completed. This discovery was made using techniques developed in geology and applied to biological samples.
Experts develop commercial formulation Campto for colorectal cancer
Announcing a new publication for Acta Materia Medica journal. The compound 7-ethyl-10-hydroxy-camptothecin (SN38) is a broad-spectrum antitumor agent whose applications are greatly limited by its poor solubility. Therefore, irinotecan, the hydrophilic derived prodrug of SN38, has been developed as the commercial formulation Campto® for colorectal cancer.
-
Founder
-
Co-ordinator
Robotic surgery programme
-
Director
-
Advisor
-
Senior Consultant
Department of Colo-rectal surgery
-
Core member
Mortality peer review group
-
Core member
Medical Records QA review group
-
Head of colorectal services
-
Associate Professor of Surgery
-
Founder
